# A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

> **NCT05011097** · PHASE1 · COMPLETED · sponsor: **Wuhan YZY Biopharma Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Y150

## Key facts

- **NCT ID:** NCT05011097
- **Lead sponsor:** Wuhan YZY Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-08
- **Primary completion:** 2023-10-23
- **Final completion:** 2024-06-25
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05011097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05011097, "A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05011097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*